Abstract:Background The risk of myocardial infarction is at least doubled in individuals with lipoprotein(a) (Lp[a]) levels >90th percentile.[1] Lp(a) may exert pro-thrombotic effects by impairing fibrinolysis. Lp(a) has a high degree of homology to plasminogen and can competitively inhibit tissue plasminogen activator (tPA)-mediated plasminogen activation and tPA-mediated clot lysis.[2] Furthermore, Lp(a) stimulates the activity of plasminogen activator inhibitor-1, the major inhibitor of the fibrinolytic system. In patients with ST-segment elevation myocardial infarction (STEMI), impaired endogenous fibrinolysis is a strong, independent risk factor for recurrent cardiovascular events,[3] but the drivers of this are not fully understood. Whether impaired endogenous fibrinolysis is related to increased Lp(a) levels in patients with STEMI, is not known. Purpose We aimed to assess the relationship between Lp(a) and endogenous fibrinolysis in patients with STEMI. Methods In a prospective, observational study, venous blood samples were drawn from patients presenting with STEMI immediately before revascularisation, after dual antiplatelet therapy but before heparin administration. Endogenous fibrinolysis was measured immediately in non-anticoagulated whole blood using the point-of-care Global Thrombosis Test, which measures the time for occlusive thrombus formation under high shear (occlusion time) and the time for spontaneous lysis of the thrombus (lysis time).[3] Assessment of Lp(a) levels, measured by particle enhanced immunoturbidimetric assay, was performed with paired plasma samples, standardized against the International Federation of Clinical Chemistry reference material SRM2B for nmol/L. Lp(a) >32 nmol/L is associated with increased risk of ischaemic heart disease. Results A total of 80 patients were included (age 64±14y, 25% females and 86% Caucasian). There was a positive correlation between Lp(a) level and lysis time (r = 0.330, P = 0.003) (Figure 1). Lysis time was significantly longer in patients with Lp(a) >32 nmol/L (2782 [1626-3683] vs. 1725 [1259-2955] s, P = 0.044). Using a cut-point of lysis time ≥2500 s previously associated with a significantly increased cardiovascular risk in patients with STEMI, we showed that Lp(a) was significantly higher in patients with lysis time ≥2500 s (40 (22-111) vs. 18 (7-73) nmol/L, P = 0.045). Table 1 shows the relationship between clinical characteristics and Lp(a) and lysis time. Lp(a) level was higher in non-Caucasian patients. There was no correlation between Lp(a) and occlusion time (r = 0.156, P = 0.168). Conclusion In patients with STEMI, longer endogenous fibrinolysis time is related to higher Lp(a) level. Raised Lp(a) levels may, in part, contribute to impaired endogenous fibrinolysis. Future studies are required to assess whether reduction in Lp(a) with novel therapies currently in phase 3 trials can favourably modulate fibrinolysis and improve clinical outcomes.Figure 1

Lipoprotein(a): a Kinetic Study of Its Influence on Fibrin-Dependent Plasminogen Activation by Prourokinase or Tissue Plasminogen Activator.

A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.

The Kinetics of Plasminogen Activation by Thrombin-Cleaved Pro- Urokinase and Promotion of Its Activity by Fibrin Fragment E-2 and by Tissue Plasminogen Activator

Relationship between lipoprotein(a) and endogenous fibrinolytic status in patients with STEMI

Fragment E-2 From Fibrin Substantially Enhances Pro-Urokinase-Induced Glu-Plasminogen Activation - A Kinetic-Study Using The Plasmin-Resistant Mutant Prourokinase Ala-158-Rpro-Uk

The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation.

Activated Thrombin-activatable Fibrinolysis Inhibitor Reduces the Ability of High Molecular Weight Fibrin Degradation Products to Protect Plasmin from Antiplasmin*

Modulation of Serpin Reaction Through Stabilization of Transient Intermediate by Ligands Bound to Α-Helix F

[Plasma Lp (a) Levels and Correlation of Lp (a) with Fibrinolysis Activation in Chronic Renal Failure].

Lp(a) Lipoprotein and Plasminogen Activity in Patients with Different Etiology of Ischemic Stroke

Inhibition of Plasminogen Activation by a Kunitz Inhibitor, Aprotinin

The Structure Basis of the Poor Fibrin Specificity of Urokinase (Ii)--the Inhibition of Urokinase A Chain 149-157 on the Fibrin Stimulated Activation of Plasminogen by Tissue Type Plasminogen Activator.

Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation.

Inactivation of the Intrinsic Activity of Pro-urokinase by Diisopropyl Fluorophosphate is Reversible

Beta2-Glycoprotein I is a Cofactor for Tissue Plasminogen Activator-Mediated Plasminogen Activation.

LPS increases plasminogen activator inhibitor type-1 expression in human endothelial cells

Evidence for A Novel Binding Protein to Urokinase-Type Plasminogen Activator in Platelet Membranes

Thrombin Stimulation of Platelets Induces Plasminogen Activation Mediated by Endogenous Urokinase-Type Plasminogen Activator

Prourokinase Activation is the Speed-limited Step of Its Catalyzed Plasminogen Activation

Mutagenesis at Pro309 of Single-Chain Urokinase-Type Plasminogen Activator Alters Its Catalytic Properties.

Functional Effects of Single Amino Acid Substitutions in the Region of Phe113 to Asp138 in the Plasminogen Activator Inhibitor 1 Molecule.